Ah, the financial markets. A bastion of calm, predictable rationality, where every policy pronouncement is meticulously analyzed, digested, and then calmly priced in over a sensible timeframe. Or not. Welcome to the era of Donald J. Trump, where market movements often resemble a particularly volatile game of Whac-A-Mole, driven less by quarterly earnings reports and more by the latest tweet, interview soundbite, or, increasingly, Truth Social post. Investors, it seems, have developed a new muscle memory: brace for impact, then pivot on a dime.<\/p>\n
Just when you thought you had a handle on U.S.-China trade relations, President Trump reminds everyone that the rulebook is, in fact, a napkin he scribbled on five minutes ago. Early October 2025 saw markets collectively flinch as Trump threatened “massive” new tariffs on Chinese goods, a move reportedly in response to China’s restrictions on rare earth minerals. The reaction was swift and decidedly negative. On October 10, the S&P 500<\/a> plunged 2.71%, the Dow Jones Industrial Average<\/a> depreciated 1.90%, and the tech-heavy Nasdaq 100<\/a>, particularly vulnerable given its reliance on rare earth minerals, plummeted a staggering 3.49%. Gold<\/a>, ever the nervous Nellies’ friend, reclaimed the $4,000 per ounce level as investors sought safe haven.<\/p>\n But fear not, for the market’s anxiety is often as fleeting as a Trumpian policy stance. Just three days later, on October 13, a single post on Truth Social<\/a> declared, “Don’t worry about China, it will all be fine!” And just like that, the markets, ever eager for a reason to breathe, rebounded with gusto. The Dow<\/a> surged over 500 points, the S&P 500<\/a> gained 1.24%, and the Nasdaq<\/a> climbed 1.54%. The collective sigh of relief was almost audible, until, of course, the next headline. On October 14, renewed trade tensions saw the Nasdaq<\/a> and S&P 500<\/a> close down 0.8% and 0.2% respectively, following another Truth Social post by the former President about China. The Dow<\/a>, seemingly immune to such whiplash, managed a 0.4% gain.<\/p>\n Fast forward to October 17, and the narrative shifted again. Trump, in an interview, suggested that his proposed 100% tariffs on Chinese goods would “not be sustainable,” simultaneously confirming an upcoming meeting with Chinese President Xi Jinping. This “more conciliatory tone” immediately prompted a “modest rebound” in key U.S. stock indices. The Dow<\/a> advanced 0.2%, the S&P 500<\/a> was near flat, and the Nasdaq<\/a>, while still down 0.1%, had recovered from steeper early losses. Gold, having peaked at a new record high of $4,392 per ounce earlier that day, pulled back by 1-2%. The market’s ability to interpret a threat as a bargaining chip, then a walk-back as a reason to celebrate, is truly a testament to its boundless optimism, or perhaps its sheer exhaustion. Yet, amidst the softening rhetoric, Trump also authorized a 25% tariff on large trucks, effective November 1st. [cite: 26 from original alerts] Because consistency is for lesser mortals, apparently.<\/p>\n The pharmaceutical industry, usually a bastion of stable, if occasionally controversial, growth, has also found itself on the receiving end of Trump’s unique brand of policy-by-announcement. On one hand, there’s the heartwarming tale of Merck KGaA. On October 17, President Trump announced a deal with the German pharmaceutical giant’s U.S. unit, EMD Serono, to slash the prices of its in vitro fertilization (IVF<\/a>) drugs by a remarkable 84% off list price when all three standard IVF medications (Gonal-f, Ovidrel, and Cetrotide) are used together. This generous discount, which the White House estimates will save families around $2,200 per IVF cycle, came with a rather convenient quid pro quo: a reprieve from future tariffs on pharmaceutical imports and an accelerated review process for Merck’s new fertility drug, Pergoveris. Merck will also be a proud participant in the upcoming “TrumpRx” direct-to-consumer platform, launching in January 2026. Analyst Michael Cherny of Leerink Partners noted the deal’s potential to boost “awareness and adoption for IVF,” even if direct financial benefits to employers are yet to materialize. A win-win, it seems, especially when tariffs are involved.<\/p>\n However, not all pharmaceutical news landed quite so softly. Just a day earlier, on October 17, during a White House event ostensibly focused on fertility treatments, Trump casually dropped a bombshell about the popular weight-loss drug Ozempic. He declared that its price would be “much lower,” potentially down to $150 a month from its current list price of around $1,000. The market’s reaction was immediate and less than enthusiastic for the drugmakers involved. Novo Nordisk<\/a> (NVO<\/a>), the maker of Ozempic, saw its shares plummet as much as 6% in early trading on Friday, eventually recovering slightly to be down about 3.5% shortly after markets opened. In Copenhagen trading, it fell as much as 7%. Not to be outdone, rival Eli Lilly<\/a> (LLY<\/a>), which sells similar GLP-1 treatments like Mounjaro and Zepbound, also saw its shares tick 4% lower, settling at about 2.6% down. Other pharmaceutical companies, including Zealand Pharma and Viking Therapeutics, also experienced declines of around 4% and 6% respectively.<\/p>\n Analysts, ever the voice of measured skepticism, quickly weighed in. BMO Capital Markets described Trump’s $150 price target as “aggressive posturing” and a “headline risk” rather than a fundamental change, pointing out that insured patients already pay significantly less, sometimes as low as $25 a month. JPMorgan analysts similarly saw “no downside to our numbers” from the mentioned price points, though they acknowledged that “to some in the market the price levels are lower than anticipated.” The Centers for Medicare & Medicaid Services Administrator, Mehmet Oz, even had to clarify that negotiations for GLP-1 drugs “have not been negotiated yet” and would be “rolled out over time.” So, a major market-moving announcement, yet no actual deal. Classic.<\/p>\n Beyond the grand pronouncements on trade and drug prices, President Trump’s preferred digital soapbox, Truth Social<\/a>, has become an unexpected barometer of market sentiment. It appears that his posts on the platform can directly influence investor confidence, and not always for the better. [cite: 16 from original alerts] The company behind Truth Social, Digital World Acquisition Corp. (DWAC<\/a>), has experienced its own rollercoaster ride, though with a decidedly downward trajectory recently. On October 10, 2025, DWAC<\/a> stock hit a rather ignominious 52-week low of $7.57. This represented a stark 67.18% year-to-date decline from its 52-week high of $44.83. While some forecasts for October 2025 optimistically predicted the stock at around $100, the reality has been far more grounded, or rather, sinking. Another forecast, updated on October 17, even predicted a further drop to $35.14 by mid-November, despite claiming a “Bullish” sentiment while simultaneously noting a “Fear” reading on the Fear & Greed Index. The contradictions are almost poetic. The takeaway? When Trump takes to Truth Social, the market listens, often with a wince and a quick check of portfolio values.<\/p>\n In conclusion, navigating the stock market under the influence of Donald Trump is less about fundamental analysis and more about rapid-fire reaction to a constantly shifting landscape of policy threats, softened stances, and impromptu announcements. From the dramatic plunges and rebounds caused by tariff rhetoric to the immediate multi-percentage point drops in pharmaceutical giants after a casual comment on drug prices, the market remains on high alert. Deals are struck, then clarified as “negotiations,” and social media posts can send billions tumbling or soaring. For investors, it’s a perpetual state of “expect the unexpected,” with a healthy side of “did he just say that?” The only consistent factor, it seems, is the sheer unpredictability. And perhaps, a good sense of humor.<\/p>\n DISCLAIMER: <\/b> We read Trump’s posts so you don’t have to. This is comedy meets market data, not financial advice. Not political advice either – we just like charts and chaos.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":" Ah, the financial markets. A bastion of calm, predictable rationality, where every policy pronouncement is meticulously analyzed, digested, and then […]<\/p>\n","protected":false},"author":8,"featured_media":50312,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[4331],"tags":[],"class_list":["post-54741","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-trump-stock-market"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/54741","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=54741"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/54741\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50312"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=54741"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=54741"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=54741"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Pharma’s Pill Problem: Deals and Dips<\/h2>\n
Truth Social and the Confidence Conundrum<\/h2>\n
The Ever-Shifting Sands<\/h2>\n